The United Kingdom and the United States have secured a significant trade agreement that will guarantee zero levies on UK medicine exports entering the US market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has committed to increase spending on medicines through the NHS. This move guarantees that import taxes on these vital goods will remain at nothing for a duration of three years.
This deal is in response to previous warnings to hike duties on patented drug imports, with figures mentioned as high as double the cost.
"This arrangement with the Britain bolsters the international landscape for cutting-edge drugs and brings long-overdue equity to transatlantic drug exports," a statement noted.
Commercial Impact
Drugs are one of the the United Kingdom's biggest exports to the US, which is by far the largest buyer for large companies like GSK and AstraZeneca.
Statistics indicate that in the 12 months prior to September, the UK shipped pharmaceutical products valued at over eleven billion pounds to the US. This value represented nearly one-fifth of total UK exports in that timeframe.
"This guarantee secures jobs, boosts investment and facilitates the UK to establish itself as a worldwide center for life sciences," a minister stated.
Key NHS Changes
The pact includes several specific changes from the United Kingdom:
- Revised Affordability Limit: The UK will raise the price threshold at which it considers new treatments to be unaffordable by twenty-five percent.
- Higher Drug Budget: There is a aim to double overall public funding on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the next decade.
- Rebate Cap: The sum manufacturers must return to the NHS to control costs will be limited at 15%. Last year, repayments were more than twenty percent.
Industry Background
The deal takes place against a long-running row between the drug companies and the British authorities over spending levels and NHS adoption.
This friction were exacerbated by arguments that American customers were paying a premium for the same drugs than consumers in the Britain and the EU.
Over the last 18 months, several large pharmaceutical investments in the UK have been delayed or abandoned, while substantial funding commitments have been pledged toward projects in the United States.
The Science Minister stated that the NHS had to spend more on treatments, noting that its expenditure on drugs had declined as a percentage of its resources over the past decade.
